Vale S.A. (VALE)
NYSE: VALE · Real-Time Price · USD
9.37
-0.17 (-1.78%)
At close: May 28, 2025, 4:00 PM
9.45
+0.08 (0.85%)
After-hours: May 28, 2025, 6:02 PM EDT
Vale S.A. Revenue
Vale S.A. had revenue of 47.41B BRL in the quarter ending March 31, 2025, with 13.18% growth. This brings the company's revenue in the last twelve months to 211.53B, up 2.62% year-over-year. In the year 2024, Vale S.A. had annual revenue of 206.01B, down -0.99%.
Revenue (ttm)
211.53B BRL
Revenue Growth
+2.62%
P/S Ratio
1.10
Revenue / Employee
3,273,874 BRL
Employees
64,610
Market Cap
40.62B USD
Revenue Chart
* This company reports financials in BRL.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 206.01B | -2.06B | -0.99% |
Dec 31, 2023 | 208.07B | -18.44B | -8.14% |
Dec 31, 2022 | 226.51B | -67.02B | -22.83% |
Dec 31, 2021 | 293.52B | 87.43B | 42.42% |
Dec 31, 2020 | 206.10B | 61.46B | 42.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BHP Group | 53.97B |
Rio Tinto Group | 53.66B |
CRH plc | 35.80B |
Linde | 33.02B |
Freeport-McMoRan | 24.86B |
The Sherwin-Williams Company | 23.04B |
Newmont | 19.67B |
Ecolab | 15.68B |
VALE News
- 11 hours ago - More Than Iron - Vale's Strategic Pivot To Critical Metals - Seeking Alpha
- 8 days ago - What's Next With VALE Stock? - Forbes
- 13 days ago - 5 Ideal 'Safer' Dividend Buys From Bloomberg's May Watchlist - Seeking Alpha
- 13 days ago - AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London - Business Wire
- 22 days ago - Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks - Seeking Alpha
- 4 weeks ago - Vale Q1: Still Undervalued? Let's Revisit The Thesis After A Challenging Quarter - Seeking Alpha
- 4 weeks ago - Rio Tinto Vs. Vale: Inventory Doesn't Lie - Seeking Alpha
- 4 weeks ago - Vale S.A. (VALE) Q1 2025 Earnings Call Transcript - Seeking Alpha